Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial
| Autor: | Yi Mo, Yuanzheng Qiu, Jianli Chu, Junhui Tao, Dingkai Wei, Xu Yang, Jilian Kong, Ming-Qiang Li, Susan S. Kaplan, Darcy A. Hille, Zhaojun Mo, Xueyan Liao, Micki Nelson, Botao Fu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Rotavirus medicine.medical_specialty Placebo-controlled study Vaccines Attenuated Placebo medicine.disease_cause Severity of Illness Index Rotavirus Infections 03 medical and health sciences 0302 clinical medicine Asian People Double-Blind Method 030225 pediatrics Internal medicine Multicenter trial medicine Animals Humans Infant Health 030212 general & internal medicine Adverse effect General Veterinary General Immunology and Microbiology business.industry Vaccination Rotavirus Vaccines Public Health Environmental and Occupational Health Infant Vaccine efficacy Rotavirus vaccine Gastroenteritis Infectious Diseases Molecular Medicine Cattle Female business |
| Zdroj: | Vaccine. 35:5897-5904 |
| ISSN: | 0264-410X |
| Popis: | Background A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). Methods 4040 participants aged 6–12 weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n = 2020) or placebo (n = 2020), administered ∼4 weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14 days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14 days after the third dose. All adverse events (AEs) were collected for 30 days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). Results VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30 days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. Conclusions In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect